spacer
home > ict > summer 2007 > building consensus
PUBLICATIONS
International Clinical Trials

Building Consensus

Henry Yau at the Clinical Trials Centre, Hong Kong, rethinks the clinical trial agreement management process

Management of clinical trial agreements/contracts (CTAs) for industry-sponsored clinical trials between sponsors and study sites has been deemed a major rate-determining step for the initiation of clinical trials. Study sites are commonly blamed by the industry for their unfamiliarity with legal parlance, incomplete knowledge of legal and regulatory requirements and requests for specific arrangements that deviate from sponsors’ standard contract terms and conditions.

Sponsors, on the other hand, are condemned by study sites for using tricky and difficult-to-understand legal jargon that is biased towards sponsors and unfair to study sites. Within a sponsor's organisation, project teams frequently accuse their legal departments of wasting time on debating meaningless legalese. Legal counsels used to complain to project teams about their overlooking potential legal risks. Such conflicting views among different parties has resulted in fewer industry players attempting to look into the issue from a broader perspective and propose holistic solutions – hence the problem persists.

CTA MANAGEMENT PROCESS

Contracts are normally seen as specifically legal documents. Drafting, negotiating and managing CTAs are, therefore, commonly regarded by many sponsors, contract research organisations (CROs) and study sites as purely legal matters and the sole responsibility of legal counsels. This, however, reflects the incomplete understanding of the functions of contracts. Whilst contracts are intended to be legally binding, the primary purpose of any contract is not to take the contract parties to court, but to set out the rights and responsibilities of those parties and, ultimately, to facilitate the accomplishment of the goals of the parties under the contract. Management of CTAs is a multi-disciplinary process involving four interlocking components (see Figure 1).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Henry Yau has a BSc in Biochemistry and a MBA in Finance. He has 14 years’ experience in the pharmaceutical and petrochemical industries. He started his career in the pharmaceutical industry with a marketing and regulatory position in Rhone-Poulenc, and subsequently assumed a business development position in a petrochemical group. Since 2000, Henry has worked at the Clinical Trials Centre of The University of Hong Kong. Henry is currently the Assistant Director and Business Development Manager of the Clinical Trials Centre, Hong Kong, and is principally responsible for managing its strategic business development functions.
spacer
Henry Yau
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo awarded with the prestigious Cargo Airline of the Year 2019 prize by the global logistics industry

 Maintaining its upward trend, Turkish Cargo was granted with the ‘Cargo Airline of the Year 2019’ award, called as the Oscar of the global logistics industry, by the global air cargo sector readers of the Air Cargo News magazine.
More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement